Physician profile
Jack E Dubose
NPI 1447217880
$746.27
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $162.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $147.14 | 2019-2020 | |
| Allergan, INC. | $96.21 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $95.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $95.65 | 2020 | |
| Sanofi Pasteur INC. | $84.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $53.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.09 | 2019 | |
| Amgen INC. | $33.00 | 2019-2020 | |
| Amarin Pharma, INC. | $19.02 | 2020 | |
| Glaxosmithkline, LLC. | $18.84 | 2019 | |
| Aytu Biopharma, INC. | $13.05 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.01 | 2019 | |
| Pfizer INC. | $11.91 | 2019 | |
| Radius Health, INC. | $11.59 | 2019 | |
| Novo Nordisk INC | $10.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Dubose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.